PRLD
Prelude Therapeutics Inc
3.70$
-3.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +7.4% | -11.0% | -9.2% | -12.1% | -11.0% | -19.5% | -18.6% | -17.5% | +49.1% | -15.3% | +58.3% | |
| – | +0.3% | -12.8% | -11.0% | -14.4% | -13.1% | -24.6% | -24.9% | -24.1% | +81.2% | -20.0% | +83.1% | |
| – | +59.1% | -2.3% | +12.6% | -60.0% | +12.0% | +222.8% | -36.1% | +84.6% | -25.8% | -38.3% | +21.0% | |
| – | +1.1% | -13.3% | -10.9% | -14.6% | -13.0% | -25.9% | -26.1% | -24.9% | +87.8% | -21.0% | +86.1% | |
| – | +100.3% | -10.4% | +15.5% | -2.9% | +8.0% | -13.6% | +2.6% | -7.3% | +100.7% | -18.2% | -6.4% | |
| – | +29.2% | -19.2% | +32.3% | -4.8% | +15.4% | -22.8% | +5.7% | -13.0% | +191.3% | -21.3% | -8.8% | |
| – | +211.8% | +47.7% | +25.2% | -0.5% | -0.9% | -1.7% | +2.2% | +0.6% | +0.6% | +0.6% | +0.7% | |
| – | -11.4% | +15.9% | +16.2% | -4.0% | +30.6% | -24.6% | -14.9% | -49.0% | +57.2% | -48.1% | -1.8% | |
| – | -0.5% | -11.1% | -13.5% | -14.2% | -16.0% | -21.5% | -26.5% | -22.8% | +17.3% | -12.3% | +122.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.9% | +8.8% | +0.0% | +0.1% | +0.1% | +0.1% | +0.0% | +0.2% | -17.3% | +31.1% | +19.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.